Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$65.37
▼ $2.63 (-3.9%)
Market data updated: 09/20 06:21 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$5.46B
Day Range
$65.18 - $68.01
52-Week Range
$57.74 - $90.87
Beta
—
Next Earnings
02.11.2026
Support
$64.57
Resistance
$89.71
PTCT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+4.0% (1Y)
Strengths: 15/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $210.83 vs. price $65.37 (+222.5%)
Fair Value
Biggest negative driver
Return on equity (ROE)
Return on equity (ROE): -332.5% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
54
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
63
Value
67
Momentum
13
Risk
62
Sentiment
56
Fundamental
66
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **PTC Therapeutics, Inc.** has centered on its **clinical progress with Sephience™ (sepiapterin)**, highlighting new trial data showing sustained metabolic control, diet liberalization, and a favorable safety profile for patients with phenylketonuria (PKU). The company also faces scrutiny over **revenue visibility**, despite a $20 million milestone payment from Takeda for its KROS program. Additionally, speculation persists about potential **acquisitions or partnerships**, including a reported $111 million bankruptcy auction deal targeting a Fabry gene therapy. Analysts remain optimistic, with Barclays raising its price target to $122, citing Sephience’s growth potential and the upcoming FDA approval of ST-920.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about PTC Therapeutics, Inc.. News trend score: 56. Reason: 6 of the last 20 articles are positive, versus 5 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
24
🎯 Conviction (vs. Emotion)
48
Psychology
75
Fundamentals
66
Technical
13
Valuation
67
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-17%
Market Narrative
25
Fundamental Reality
48
Narrative Gap
-23
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant herding behavior suggests traders are passively aligning PTCT’s -0.7% drop with broader peer declines (-1.7%), lacking aggressive conviction or panic. Low FOMO (score 5) and muted volume (0.95x avg) imply limited urgency, while restrained panic (score 15) and neutral RSI (41) suggest no extreme distress. The narrative gap (-16) hints at a disconnect where sentiment (32) lags reality (48), possibly reflecting cautious optimism or delayed reaction to fundamentals. The key question: *Is this herding a temporary alignment or a structural shift in sector positioning?*
Updated: 09/08/2026, 04:19 PM
What could change this?
👥 What the crowd believes
"PTC Therapeutics to Participate in Upcoming Investor Conferences"
"PTC Therapeutics Announces New Sephience™ Data Reinforcing Broad Patient Benefits"
"PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal"
📈 8D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 99/100
🔴 Weakest match
Jesse Livermore — 21/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with the highest-scoring approaches—Benjamin Graham’s defensive and enterprising frameworks, Peter Lynch’s growth philosophy, and Philip Fisher’s quality-focused criteria—all converging on near-unanimous bullishness. Graham’s models see it as a statistically discounted bargain, while Lynch and Fisher highlight its growth potential and exceptional fundamentals, respectively. Meanwhile, mid-tier thinkers like Howard Marks (market-cycle) and Samuel Nelson’s cycle analysis also lean positive, though with slightly more caution, suggesting it’s not yet overextended. In contrast, the more conservative or contrarian voices—such as Morgan Housel’s patient compounding lens, the efficient-market proponents, and even Gerald Loeb’s capital-preservation stance—still view it favorably, though with less enthusiasm. The split widens dramatically at the extremes: Thorstein Veblen and Jack Schwager’s neutral scores hint at uncertainty over profitability, while Jesse Livermore’s near-total rejection aligns with his strict trend-following rule, making it the lone outlier in this otherwise optimistic debate.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 99
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 98
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 96
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 96
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 95
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 94
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 40%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 88
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 88
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 86
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟢 73
A real, well-supported case — deviating from a broad index may be justified here
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 72
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 71
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 68
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 21
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
50.1%
Net Margin
39.4%
EBITDA Margin
52.3%
ROE
-332.5%
ROA
23.5%
ROIC
—
EPS
$8.58
Cash
$984.65M
Total Debt
$286.63M
Current Ratio
2.35
Debt/Equity
-1.40
How is Fair Value calculated? →
Current Price
$65.37
Estimated Fair Value (DCF)
$210.83
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+222.5%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $877.92M | $805.43M |
| 2 | 19.4% | $1.05B | $882.09M |
| 3 | 13.8% | $1.19B | $920.53M |
| 4 | 8.1% | $1.29B | $913.15M |
| 5 | 2.5% | $1.32B | $858.69M |
Base FCF (last actual year)
$702.34M
Terminal Value
$20.83B
Present Value of Terminal Value
$13.54B
Enterprise Value
$17.92B
Net Debt
$-698.02M
Equity Value
$18.62B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
-$2.32
Tangible Book Value per Share (Tangible NAV)
-$7.66
Sentiment based on basic keywords (not AI) — 6 positive, 9 neutral, 5 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 17.9.2026
SeekingAlpha · 15.9.2026
Trefis · 4.9.2026
Yahoo · 27.8.2026
PR Newswire · 27.8.2026
Zacks · 24.8.2026
Zacks · 24.8.2026
PR Newswire · 24.8.2026
Benzinga · 24.8.2026
SeekingAlpha · 24.8.2026
GuruFocus.com · 17.8.2026
MarketBeat · 16.8.2026
Benzinga · 14.8.2026
Benzinga · 13.8.2026
BioPharma Dive · 13.8.2026
Benzinga · 13.8.2026
SeekingAlpha · 13.8.2026
GlobeNewswire · 12.8.2026
PR Newswire · 12.8.2026
PTC Therapeutics, Inc. (PTCT) currently has a StockIQ AI score of 54/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
PTCT currently scores 54/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, PTCT's estimated fair value is $210.83, which is 222.5% above the current price of $65.37. This is one valuation model among several signals in the fair-value category, not a price target.
PTCT's technical score is 13/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $210.83 vs. price $65.37 (+222.5%); Revenue growth (last year): 114.5%; Earnings per share (EPS) growth: 264.5%.
Based on the real signals StockIQ computed: Return on equity (ROE): -332.5% (negative); Price is below the 50-day average; Price is below the 200-day average.
StockIQ has no recorded dividend payment history for PTCT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 20 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| SCHMERTZLER MICHAEL | Open Market Sale | 10.9.2026 | 10,000 | -10,000 | $67.34 |
| SCHMERTZLER MICHAEL | Open Market Sale | 9.9.2026 | 9,428 | -9,428 | $67.79 |
| SCHMERTZLER MICHAEL | Open Market Sale | 9.9.2026 | 572 | -572 | $68.67 |
| SCHMERTZLER MICHAEL | Open Market Sale | 27.8.2026 | 1,337,204 | -11,890 | $71.55 |
| SCHMERTZLER MICHAEL | Open Market Sale | 27.8.2026 | 1,336,594 | -610 | $72.22 |
| SCHMERTZLER MICHAEL | Open Market Sale | 27.8.2026 | 610 | -610 | $72.22 |
| SCHMERTZLER MICHAEL | Open Market Sale | 27.8.2026 | 11,890 | -11,890 | $71.55 |
| SCHMERTZLER MICHAEL | Open Market Sale | 26.8.2026 | 1,354,720 | -6,874 | $72.74 |
| SCHMERTZLER MICHAEL | Open Market Sale | 26.8.2026 | 1,349,094 | -5,626 | $73.18 |
| SCHMERTZLER MICHAEL | Open Market Sale | 26.8.2026 | 5,626 | -5,626 | $73.18 |
| SCHMERTZLER MICHAEL | Open Market Sale | 26.8.2026 | 6,874 | -6,874 | $72.74 |
| SCHMERTZLER MICHAEL | Open Market Sale | 20.8.2026 | 9,419 | -9,419 | $70.78 |
| SCHMERTZLER MICHAEL | Open Market Sale | 20.8.2026 | 691 | -691 | $72.92 |
| SCHMERTZLER MICHAEL | Open Market Sale | 20.8.2026 | 2,390 | -2,390 | $71.88 |
| SCHMERTZLER MICHAEL | Open Market Sale | 19.8.2026 | 7,165 | -7,165 | $73.67 |
| SCHMERTZLER MICHAEL | Open Market Sale | 19.8.2026 | 5,335 | -5,335 | $72.86 |
| Boulding Mark Elliott | Exercise of Derivative Securities | 17.8.2026 | 2,813 | -2,813 | — |
| Boulding Mark Elliott | Open Market Sale | 17.8.2026 | 1,844 | -1,844 | $72.39 |
| Boulding Mark Elliott | Exercise of Derivative Securities | 17.8.2026 | 2,813 | +2,813 | $25.69 |
| Boulding Mark Elliott | Open Market Sale | 17.8.2026 | 969 | -969 | $72.90 |
| Klein Matthew B. | Open Market Sale | 4.8.2026 | 10,292 | -10,292 | $68.57 |
| Klein Matthew B. | Open Market Sale | 4.8.2026 | 383,868 | -10,292 | $68.57 |
| Sollie-Zetlmayer Hege Elisabeth | Grant/Award from Employer | 28.7.2026 | 1,738 | +1,738 | — |
| Sollie-Zetlmayer Hege Elisabeth | Grant/Award from Employer | 28.7.2026 | 3,475 | +3,475 | — |
| Sollie-Zetlmayer Hege Elisabeth | Grant/Award from Employer | 28.7.2026 | 4,000 | +4,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
9,828,154 shares short as of 2026-08-31 · vs. 10,566,249 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
55.6% of trading volume this week was short selling, vs. 61.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology